Detalhe da pesquisa
1.
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Clin Immunol
; 155(2): 160-75, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25444722
2.
Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.
Clin Dev Immunol
; 2013: 195691, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382970
3.
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.
Oncoimmunology
; 7(7): e1440169, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29900044
4.
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
J Hematol Oncol
; 10(1): 4, 2017 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057014
5.
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.
Clin Cancer Res
; 23(5): 1156-1166, 2017 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27582488
6.
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.
Signal Transduct Target Ther
; 1: 16002, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263894